Aghajanian, C., Filiaci, V., Dizon, D. S., Carlson, J. W., Powell, M. A., Secord, A. A., . . . Levine, D. A. (2018). A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecologic oncology, 150(2), 274-281. https://doi.org/10.1016/j.ygyno.2018.05.018
Citácia podle Chicago (17th ed.)Aghajanian, Carol, et al. "A Phase II Study of Frontline Paclitaxel/carboplatin/bevacizumab, Paclitaxel/carboplatin/temsirolimus, or Ixabepilone/carboplatin/bevacizumab in Advanced/recurrent Endometrial Cancer." Gynecologic Oncology 150, no. 2 (2018): 274-281. https://doi.org/10.1016/j.ygyno.2018.05.018.
Citácia podľa MLA (8th ed.)Aghajanian, Carol, et al. "A Phase II Study of Frontline Paclitaxel/carboplatin/bevacizumab, Paclitaxel/carboplatin/temsirolimus, or Ixabepilone/carboplatin/bevacizumab in Advanced/recurrent Endometrial Cancer." Gynecologic Oncology, vol. 150, no. 2, 2018, pp. 274-281, https://doi.org/10.1016/j.ygyno.2018.05.018.